高流量鼻疗对心脏术后肺部并发症高风险患者以患者为中心结局的影响:多中心适应性随机对照试验研究方案
本研究为多中心、国际、平行组、适应性随机对照试验,纳入心脏术后呼吸并发症高风险患者,比较拔管后预防性高流量鼻疗与标准氧疗对90天内存活且在家天数的影响,并评估成本效果。预计需850例患者以90%把握度检出DAH90增加2天,期中样本量重估后最多可增至1152例。
要点
- 心脏术后拔管后使用高流量鼻疗至少16小时,与标准氧疗比较DAH90。
- 主要目标为90天内存活且在家天数增加,共同主要目标为90天成本效果。
- 样本量850例,期中重估后最多增至1152例,检验把握度90%。
核心结论
- 该研究方案旨在确定心脏术后拔管后预防性高流量鼻疗是否较标准氧疗增加90天内存活且在家天数,并评估其成本效果。
研究设计与样本
- 多中心、国际、平行组、适应性随机对照试验,嵌入成本效果分析,比较心脏术后呼吸并发症高风险患者拔管后高流量鼻疗与标准氧疗。
- 参与者在气管拔管前随机,分配至高流量鼻疗或标准氧疗,拔管后立即至少16小时,随访至术后90天。
- 检测DAH90增加2天、把握度90%、意向性分析所需总样本量为850例患者。
- 适应性设计包括期中样本量重估,允许最大样本量增至1152例。
关键数值与推荐
- 主要目标:比较拔管后预防性高流量鼻疗与标准氧疗对术后90天内存活且在家天数的影响。
- 共同主要目标:从公共部门、卫生服务和患者视角估计90天时高流量鼻疗对比标准氧疗的增量成本效果和成本效用。
- 样本量:检测DAH90增加2天、90%把握度、意向性分析需850例患者;期中重估后最大样本量可增至1152例。
局限性
- 原文指出缺乏评估心胸外科术后高流量鼻疗临床和成本效果的高质量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-flow nasal therapy is a non-invasive form of respiratory support that delivers low-level, flow dependent positive airway pressure. The device can be better tolerated by patients than alternatives such as continuous positive airway pressure. The primary objective is to determine if prophylactic high-flow nasal therapy after tracheal extubation can result in an increase in the number of days alive and at home within the first 90 days after surgery, when compared with standard oxygen therapy. The co-primary objective is to estimate the incremental cost-effectiveness and cost-utility of high-flow nasal therapy vs standard oxygen therapy at 90 days, from the view-point of the public sector, the health service and patients. METHODS: This is an adaptive, multicentre, international parallel-group, randomised controlled trial with embedded cost-effectiveness analysis comparing the use of high-flow nasal therapy with control in patients at high risk of respiratory complications following cardiac surgery. Participants will be randomised before tracheal extubation and allocated either high-flow nasal therapy or standard oxygen therapy for a minimum of 16 h immediately post extubation. Participants will be followed up until 90 days after surgery. The total sample size needed to detect a 2-day increase in DAH90 with 90% power with an intention to treat analysis is 850 patients. The adaptive design includes an interim sample size re-estimation which will provide protection against deviations from the original sample size assumptions made from the single-centre pilot study and will allow for a maximum sample size increase to 1152 patients. DISCUSSION: Evidence to support routine use of high-flow nasal therapy will inform the development of effective enhanced recovery care bundles. Reducing complications should reduce length of stay and re-admission to hospital and provide an important focus for cost reduction. However; high-quality studies evaluating the clinical and cost effectiveness of high-flow nasal therapy after cardiothoracic surgery are lacking. TRIAL REGISTRATION: The study has been registered with ISRCTN ( ISRCTN14092678 , 13/05/2020) Clinicaltrials.gov Registration Pending.
引用
- Earwaker M, Villar S, Fox-Rushby J, et al. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: a study protocol for a multicentre adaptive randomised controlled trial. Trials. 2022. PMID: 35346339. doi:10.1186/s13063-022-06180-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。